The Government of India has launched the ₹2000 crore Biotechnology Research and Development Innovation (RDI) Fund through BIRAC to fast-track high-impact biotech R&D. The fund targets translational research, early-stage startups, deep-tech innovations, and public-private partnerships, aiming to position India as a global leader in biotechnology and life sciences.
Glimpse:
Administered by the Biotechnology Industry Research Assistance Council (BIRAC), the ₹2000 crore RDI Fund will support proof-of-concept, scale-up, clinical validation, and commercialization of breakthrough biotech solutions. Priority areas include vaccines, therapeutics, diagnostics, regenerative medicine, synthetic biology, and bio-manufacturing. The initiative offers grants, equity, loans, and milestone-based funding with relaxed eligibility norms to encourage risk-taking in deep science and medtech.
In a landmark move to strengthen India’s biotech ecosystem, the Department of Biotechnology (DBT) under the Ministry of Science and Technology has launched the ₹2000 crore Biotechnology Research and Development Innovation (RDI) Fund. The fund, managed by BIRAC (Biotechnology Industry Research Assistance Council), was officially unveiled in early 2026 and is designed to bridge the critical gap between discovery research and market-ready products.
The RDI Fund will operate through multiple windows: Early-stage grants for proof-of-concept and lab-to-market validation Equity and convertible debt for promising startups and spin-offs Milestone-linked funding for scale-up, regulatory trials, and manufacturing readiness Industry-academia consortia support for collaborative high-risk projects
Key focus domains include: Advanced therapeutics (cell & gene therapy, mRNA platforms, monoclonal antibodies) Vaccines & biologics (next-gen platforms, pandemic preparedness) Diagnostics & precision medicine (point-of-care, AI-enabled tools) Synthetic biology & bio-foundries Regenerative medicine & tissue engineering Bio-manufacturing & sustainable biotech
The fund introduces more flexible terms than previous BIRAC schemes higher funding caps, faster approvals, and reduced equity dilution for early innovators. It also prioritizes women-led teams, deep-tech ventures, and projects addressing unmet needs in India (rare diseases, antimicrobial resistance, maternal & child health).
The launch aligns with the BioE3 Policy (Biotechnology for Economy, Environment & Employment) and the government’s ambition to grow India’s biotech sector to $150 billion by 2030. BIRAC expects the fund to catalyse hundreds of new startups, strengthen translational research, and position Indian biotech firms as global competitors in high-value areas.
This is one of the largest dedicated biotech innovation funds announced by any government in recent years, sending a strong signal of India’s commitment to science-led economic growth.
“₹2000 crore is not just money it’s rocket fuel for Indian biotech to leap from discovery to global
By
HB Team
